medigraphic.com
ISSN 1684-1824 (Electronic)

2019, Number 5

<< Back Next >>

Rev Méd Electrón 2019; 41 (5)

An approach to the treatment of the cirrhotic patient

Arredondo BAE, Trujillo PY, Chiong QM

Language: Portugués
References: 29
Page: 1269-1278
PDF size: 115.15 Kb.


ABSTRACT

Cirrhosis is a reversible status of the liver fibrosis, being the 8th cause of death in the United States and the 9th cause of death in Cuba. This article reviews the practical treatment of cirrhosis based on the review of clinical research published in MEDLINE, HINARI and Scielo, during the last years. The main causes of hepatic cirrhosis include the chronic hepatitis caused by B and C viruses, alcoholism, and the non-alcoholic steato-hepatitis. Malnutrition occurs in 20-60 % of the patients with cirrhosis, therefore low protein diets are under revision; it is recommended a strict use of salt; the use of drugs should be strictly evaluated. Hypotensive drugs should be cautiously used when the average arterial tension is lower than 82 Hg mm. Non-selective betablockers are indicated in developed esophageal varices. It is also recommended to be cautious with analgesics and proton pump inhibitors while the statins use is not restricted. Regarding the invasive procedures, surgery should be evaluated very carefully, and the MELD index can help with respect to prognosis and expected mortality. In refractory ascites, paracentesis should be massive relayed on albumin use, and should be carried out as soon as possible in the suspicion of spontaneous bacterial peritonitis. In conclusion, the adequate nutrition use, the control of complications and risk factors, could lead to reversibility of hepatic cirrhosis.


REFERENCES

  1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71.Citado en PubMed:PMID:25530442.

  2. MINSAP. Anuario estadístico de salud. Cuba 2016[Internet]. La Habana: Ministerio de salud pública. Dirección de registros médicos y de estadísticas de salud[citado 29/08/2017]; 2017 Disponible en: http://www.sld.cu/sitios/dne/

  3. Phillip S, Bruce A R. Treatment of Patients with Cirrhosis. N Engl J Med. 2016; 375(8):767-77. Citado en PubMed:PMID: 27557303.

  4. Ratib S, Fleming K M, Crooks, et al. Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study. Am J Gastroenterol 2015; 110(8): 1149. Citado en PubMed:PMID:26169512.

  5. Khoury AC, Klimack WK, Wallace C, et al. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2012;19(3):153-60. Citado en PubMed:PMID:22329369.

  6. Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and nonhaemodynamic effects of â-blockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012;61(7):967-9. Citado en PubMed:PMID:22234982.

  7. Córdoba J, López-Hellín J, Planas M. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38-43. Citado en PubMed:PMID:15246205.

  8. Llach J, Ginès P, Arroyo V. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988;94(2):482-7. Citado en PubMed:PMID: 3335320.

  9. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60(3):643-53. Citado en PubMed:PMID:24076364.

  10. Mandorfer M, Bota S, Schwabl P. Nonselective â blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146(7):1680-90. Citado en PubMed:PMID :24631577.

  11. Sersté T, Njimi H, Degré D, et al. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis. Liver Int. 2015;35(8):1974-82. Citado en 5ubMed:PMID: 25611961.

  12. Catalina-Rodríguez M V, Pérez-Valderas D, Ibáñez-Samaniego L, et al. Hipertensión portal. Medicine[Internet]. 2016 [citado 04/09/2017];12(11):606-16. Disponible en: http://www.sciencedirect.com/science/article/pii/S0304541216300592

  13. Carpio A, Cárdenas A. Manejo del sangrado por varices esofágicas en pacientes con cirrosis. Rev Experiencia Méd [Internet]. 2016 [citado 04/09/2017];34(2). Disponible en: http://www.experienciamedicahp.com.ar/uploads/revision-1-6234.pdf

  14. Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol [Internet]. 2015 [citado 04/09/2017];63:743-52. Disponible en: http://www.journal-of-hepatology.eu/article/S0168-8278%2815%2900349- 9/abstract

  15. Singh V, Dhungana SP, Singh B. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012;56(2):348-54. Citado en PubMed:PMID:21749847.

  16. Akhter A, Pulla A, Said A. Revisión de los tratamientos farmacológicos actuales y futuros de la esteatohepatitis no alcohólica. Clin Liver Dis 2016;8(Supl1):S34- S38.Citado en PubMed:PMID:31041094.

  17. Peña A M, Sánchez A C, Carrión L. Manejo de las urgencias del paciente cirrótico. Medicine[Internet]. 2016 [citado 04/09/2017];12(11):650-55. Disponible en:http://www.sciencedirect.com/science/article/pii/S0304541216300658

  18. O’Leary JG, Reddy KR, Wong F. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2015;13(4):753-9.e1. Citado en PubMed:PMID:25130937.

  19. Russo MW, Hoofnagle JH, Gu J. Spectrum of statin hepatotoxicity: experience of the Drug-Induced Liver Injury Network. Hepatology [Internet] 2014;60(2):679-86. Citado en PubMed:PMID:24700436.

  20. Pareja J S, Restrepo J C. Diagnostic Methods in Portal Hypertension. Rev Colombiana de Gastroenterol [Internet]. 2016 [citado 04/09/2017];31(2):135-45. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120- 99572016000200006"pid=S0120-99572016000200006

  21. Chang TS, Wu YC, Tung SY. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol. 2015;110(6):836-44. Citado en PubMed PMID:25869392.

  22. Wong F, Watson H, Gerbes A. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2012;61(1):108-16. Citado en PubMed PMID:21836029.

  23. Torres VE, Chapman AB, Devuyst O. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-18. Citado en PubMed;PMID:23121377.

  24. Navia EE, Henao H, Ferrada R. Interposición de mesentérico-cava para tratamiento de la hipertensión portal y várices esofágicas sangrantes. Colombia Médica [Internet]. 2017 [citado 04/09/2017];12(1):7-12. Disponible en: http://colombiamedica.univalle.edu.co/index.php/comedica/article/view/3363

  25. Muñoz-Navas M, Betés M. Protocolo de indicaciones, contraindicaciones y complicaciones de la endoscopia en el tracto digestivo superior. Medicine [Internet]. 2016 [citado 04/09/2017];12(3):152-6. Disponible en: http://www.sciencedirect.com/science/article/pii/S0304541216000366

  26. Llop E, Seijo S. Actuación ante la trombosis portal no cirrótica no tumoral. Gastroenterología y Hepatología [Internet]. 2016 [citado 04/09/2017];39(6):403-10. Disponible en: http://www.sciencedirect.com/science/article/pii/S0210570515002307

  27. Morando F, Maresio G, Piano S. How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol. 2013;59(2):257-64. Citado en PubMed:PMID:23523582.

  28. Kim JJ, Tsukamoto MM, Mathur AK. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol. 2014;109(9):1436-42. Citado en PubMed:PMID:PMID:25091061.

  29. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012;56(5):1171-80. Citado en PubMed:PMID:22245903.




2020     |     www.medigraphic.com